logo conference-reports

Conference Reports

При финансовой поддержке logo MSD Oncology

ESMO 2019 — Metastatic castration-resistant prostate cancer: olaparib improves PFS and interim OS in selected patients

“Practice-changing” study is first success with targeted therapy in this setting.